Hakan UZUNOĞLU, Selçuk KAYA

Rektum Kanserinde Preoperatif NLR ve PLR’nin Kısa Dönem Sağkalımda Prediktif Değeri

Giriş: Bu çalışmada NLR ve PLR değerlerinin rektal kanser olgularında hem tanıda hem de 2 ve 3 yıllık kısa dönem sağkalım hakkında prognostik belirteç olarak kullanılabilirliğinin araştırılması amaçlanmıştır. Yöntem: Çalışmaya Ocak 2015 ile Aralık 2019 arasında rektum kanseri nedeniyle opere olan ve hastanemiz Genel Cerrahi kliniğinde takip edilen 121 hasta ve çeşitli amaçlarla kliniğimize başvuran 120 sağlıklı birey dahil edilmiştir. Bulgular: Ortalama yaş 61,7±11,5 (aralık: 35-86) yıl idi. 2 ve 3 yıllık sağkalım oranları sırasıyla %63,2 ve %54,9 idi. Ortalama NLR ve PLR sırasıyla 3,6±5,2 (aralık 0,2-55) ve 171,8±169,7 (aralık 29,4-2000) idi. Ortalama 2 ve 3 yıllık sağkalım süreleri 19,6±8,3 ay ve 26,2±13,9 ay idi. Hasta grubunda medyan nötrofil sayısı, trombosit sayısı, NLR ve PLR kontrol grubuna göre anlamlı yüksekti, medyan lenfosit sayısı ise anlamlı düşüktü (her biri için p0,05). Sonuç: Çalışmamızda elde edilen bulgular rektum kanseri hastalarında NLR ve PLR değerlerinin rektum kanserinin saptanmasında belirteç olarak kullanılabileceğini ancak 2 ve 3 yıllık sağkalım konusunda anlamlı bilgi vermediğini işaret etmektedir.

Predictive Value of Preoperative NLR and PLR in Short-term Survival in Rectal Cancer

Objective: It was aimed to investigate the use of NLR and PLR values both in diagnosis and as prognostic markers for 2- and 3-year short-term survival in rectal cancer cases. Method: The study included 121 patients who were operated for rectal and followed up in the General Surgery clinic of our hospital, and 120 healthy individuals who applied to our clinic for various purposes. Results: The mean age was 61.7±11.5 (min.-max.: 35-86) years. The 2- and 3-year survival rates were 63.2% and 54.9%, respectively. The mean NLR and PLR were 3.6±5.2 (min.-max.: 0.2-55) and 171.8±169.7 (min.-max.: 29.4-2000), respectively. The mean 2- and 3-year survival times were 19.6±8.3 and 26.2±13.9 months, respectively. In the patient group, the median neutrophil count, platelet count, NLR and PLR were significantly higher than the control group, while the median lymphocyte count was significantly lower (p0.05 for each). Conclusion: The findings obtained in the present study show that NLR and PLR values can be used as markers in the detection of rectal cancer, however that they do not provide significant information about 2- and 3-year survival.

PDF

___

1. McCourt M, Armitage J, Monson JR. Rectal cancer. Surgeon. 2009;7:162-9.
2. Legoux JL,LehurPA, PennaC,Calais G,Roseau G, Calan LD. Rectal cancer. Gastroenterol Clin Biol. 2006;30:2S43-51.
3. Wilkinson N. Management of Rectal Cancer. Surg Clin North Am. 2020;100:615-28.
4. Bhattacharjee D, Quirke P. What is the Role of the Neutrophil: Lymphocyte Ratio in Colorectal Cancer? Turk J Colorectal Dis. 2021;31:1-12.
5. Dong YW, Shi YQ, He LW, Su PZ. Prognostic significance of neutrophil-to-lymphocyte ratio in rectal cancer: a meta-analysis. Onco Targets Ther. 2016;9:3127-34.
6. Portale G, Cavallin F, Valdegamberi A, Frigo F, Fiscon V. Platelet-to-Lymphocyte Ratio and Neutrophil-to-Lymphocyte Ratio Are Not Prognostic Biomarkers in Rectal Cancer Patients with Curative Resection. J Gastrointest Surg. 2018;22:1611-8.
7. De Felice F, Rubini FL, Romano L, Bulzonetti N, Caiazzo R, Musio D, et al. Prognostic significance of inflammatory-related parameters in patients with anal canal cancer. Int J Colorectal Dis. 2019;34:519-25.
8. Braun LH, Baumann D, Zwirner K, Eipper E, Hauth F, Peter A, et al. Neutrophil-toLymphocyte Ratio in Rectal Cancer-Novel Biomarker of Tumor Immunogenicity During Radiotherapy or Confounding Variable? Int J Mol Sci. 2019;20:2448.
9. Catal O, Ozer B, Sit M. Prediction of Lymph Node Metastasis in Colon Cancer via Platelet to Lymphocyte Ratio and Platelet Count. J Coll Physicians Surg Pak. 2020;30:250-3.
10. Durhan A, Senlikci A, Kosmaz K, Erguder E, Mercan U, Suleyman M. An Evaluation of the Effect of Preoperative Inflammation-based Factors on Survival in Gastric Cancer Patients. J Coll Physicians Surg Pak. 2021;31:282-7.
11. Kim TG, Park W, Kim H, Choi DH, Park HC, Kim SH, et al. Baseline neutrophillymphocyte ratio and platelet-lymphocyte ratio in rectal cancer patients following neoadjuvant chemoradiotherapy. Tumori. 2019;105:434-40.
12. Ke TM, Lin LC, Huang CC, Chien YW, Ting WC, Yang CC. High neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio predict poor survival in rectal cancer patients receiving neoadjuvant concurrent chemoradiotherapy. Medicine (Baltimore). 2020;99:e19877.
13. Ishikawa D, Nishi M, Takasu C, Kashihara H, Tokunaga T, Higashijima J, et al. The Role of Neutrophil-to-lymphocyte Ratio on the Effect of CRT for Patients With Rectal Cancer. In Vivo. 2020;34:863-8.
14. Jeon BH, Shin US, Moon SM, Choi JI, Kim MS, Kim KH, et al. Neutrophil to Lymphocyte Ratio: A Predictive Marker for Treatment Outcomes in Patients With Rectal Cancer Who Underwent Neoadjuvant Chemoradiation Followed by Surgery. Ann Coloproctol. 2019;35:100-6.
15. Lino-Silva LS, Salcedo-Hernández RA, RuizGarcía EB, García-Pérez L, Herrera-Gómez Á. Pre-operative Neutrophils/Lymphocyte Ratio in Rectal Cancer Patients with Preoperative Chemoradiotherapy. Med Arch. 2016;70:256- 60.
16. Andras D, Crisan D, Craciun R, Nemes A, Caziuc A, Drasovean R, et al. Neutrophil-tolymphocyte ratio: a hidden gem in predicting neoadjuvant treatment response in locally advanced rectal cancer? J BUON. 2020;25:1436-42.
17. Ergen ŞA, Barlas C, Yıldırım C, Öksüz DÇ. Prognostic Role of Peripheral NeutrophilLymphocyte Ratio (NLR) and PlateletLymphocyte Ratio (PLR) in Patients with Rectal Cancer Undergoing Neoadjuvant Chemoradiotherapy. J Gastrointest Cancer. 2021. https://doi.org/10.1007/s12029-020-00578-7
18. Sun Y, Zhang Y, Huang Z, Lin H, Lu X, Huang Y, et al. Combination of Preoperative Plasma Fibrinogen and Neutrophil-to-Lymphocyte Ratio (the F-NLR Score) as a Prognostic Marker of Locally Advanced Rectal Cancer Following Preoperative Chemoradiotherapy. World J Surg. 2020;44:1975-84.
19. Timudom K, Akaraviputh T, Chinswangwatanakul V, Pongpaibul A, Korpraphong P, Petsuksiri J, et al. Predictive significance of cancer related-inflammatory markers in locally advanced rectal cancer. World J Gastrointest Surg. 2020;12:390-6.
20. Xia LJ, Li W, Zhai JC, Yan CW, Chen JB, Yang H. Significance of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, lymphocyteto-monocyte ratio and prognostic nutritional index for predicting clinical outcomes in T1-2 rectal cancer. BMC Cancer. 2020;20:208.
21. Mo CJ, Hu ZJ, Qin SZ, Chen HP, Huang L, Li S, Cao Z. Diagnostic value of plateletlymphocyte ratio and hemoglobin-platelet ratio in patients with rectal cancer. J Clin Lab Anal .2020;34:e23153.
22. Emir S, Aydin M, Can G, Bali I, Yildirim O, Öznur M, et al. Comparison of colorectal neoplastic polyps and adenocarcinoma with regard to NLR and PLR. Eur Rev Med Pharmacol. Sci 2015;19:3613-8.
23. Jia J, Zheng X, Chen Y, Wang L, Lin L, Ye X, et al. Stage-dependent changes of preoperative neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in colorectal cancer. Tumour Biol. 2015;36:9319-25.
24. Ward WH, Goel N, Ruth KJ, Esposito AC, Lambreton F, Sigurdson ER, et al. Predictive Value of Leukocyte- and Platelet-Derived Ratios in Rectal Adenocarcinoma. J Surg Res. 2018;232:275-82.
25. Mercier J, Voutsadakis IA. The plateletsneutrophils to lymphocytes ratio: a new prognostic marker in metastatic colorectal cancer. J Gastrointest Oncol. 2018;9:478-86.